We provide the state-of-the-art medical treatments to patients with diverse liver diseases and perform clinical and basic researches to improve the prognosis of patients. Our laboratory has focused on acute liver failure (ALF) and non-alcoholic fatty liver diseases (NAFLD)/non-alcoholic steatohepatitis (NASH). Kyushu University Hospital is one of the highest-volume centers for ALF therapy in Japan and we have demonstrated that intrahepatic hyper-coagulation is one of the pathogeneses of ALF. We also reported the ratio of alanine aminotransferase (ALT) to lactate dehydrogenase (LDH) is a useful predictor of intrahepatic hypoxia.
Recently, the prevalence of NAFLD/NASH has increased drastically in Japan, however, no medication is available so far. We have tried to elucidate the pathogenesis of NAFLD/NASH using human liver biopsy samples and mouse models of human NASH to develop novel therapeutic strategies for NASH.